As the global healthcare industry shifts and transforms, so too must the life science industry. Life science companies will need to adjust strategies to a world in which only true innovation and improved patient outcomes become the key determinant of value in the healthcare system. They will also need to develop commercial models which take account of the changing power balance between provider, payer and patients-all the while keeping a watchful eye on the competitive landscape for the incursion of non-traditional players with whom they will increasingly compete-or partner- to deliver patient-centred products and services. Meanwhile, scrutiny of high prices for speciality drugs and advanced technologies is increasing, impacting the ability of life science companies to bring much needed innovation to patients.
How will the industry’s future unfold?
The FT Global Pharmaceutical and Biotechnology Conference, now in its 33rd successful year, is a must-attend for industry executives, thought leaders and investors wishing to keep abreast of the emerging trends reshaping the global healthcare and life sciences industry.